Laurus Labs Ltd News

Laurus Labs zooms 73% in 2025, hits new high; what's driving pharma stock?

Laurus Labs management said the fundamentals of the company's business remain strong, with sustained growth momentum in the Contract Development and Manufacturing Organization and Generic business.

7 stocks gain up to 104% in FY26 as PAT up over 50% in Q1, Q2; Buy or sell?

BSE, Hitachi Energy, GE Vernova, Syrma SGS, Force Motors, HBL Engineering and Laurus Labs have gained more than 50% each after these companies reported over 50% growth in profit in Q1 and Q2 of FY26.

Dividend stocks: Coforge, Laurus Labs, 5 others to remain in focus today

Among the companies trading ex-dividend on Friday, Coforge has declared an interim dividend of ₹4 per share, with the record date set for the same day

M&M, HDFC Bank, Laurus Labs among Motilal Oswal's top growth bets; Check TP

HDFC Bank (HDFCB) reported a steady Q2FY26, with profit rising 11 per cent Y-o-Y to ₹186.4 billion, aided by healthy NII of ₹315.5 billion and strong treasury gains of ₹23.9 billion

Laurus zooms 105% in 1 year, hits new high. Should you buy, hold or sell?

Thus far in the month of October 2025, Laurus Labs has outperformed the market by surging 14 per cent.

Laurus Labs shares drop 3% despite analysts' bullish outlook; details here

Laurus Labs reported a strong Q2 FY26 performance, with consolidated net profit soaring multifold to ₹194.97 crore, compared with ₹19.78 crore in Q2 FY25

Q2 results today: HUL, Colgate, Laurus Labs among 11 firms on Oct 23

Q2FY26 company results: Many firms including PTC India Financial Services, Tata Teleservices, Jumbo Bag and Vardhman Textiles are also to release their July-September quarter earnings reports today

Pfizer soars 8%; Sun, Lupin gain up to 4%; here's what triggered the rally

Pfizer-US trade deal triggers rally in pharma stocks. Nifty Pharma and BSE Healthcare index jumped 1 per cent each; while Nifty 50 and BSE Sensex advanced 0.1 per cent each in Wednesday's early trade.

Laurus Labs soars 6% in 2 days, market cap tops ₹ 50,000 crore; here's why

At 11:29 AM, Laurus Labs' stock was quoting 2 per cent higher at ₹943.15 on the BSE, commanding an m-cap of ₹50,913 crore, exchange data shows

Laurus Labs gains 3%, nears record high; should you buy, hold or sell?

Thus far in September, the stock price of Laurus Labs has rallied 6 per cent, as compared to a 1.5 per cent rise in the BSE Sensex and BSE Healthcare index

Sun, Lupin, Dr Reddy's drop up to 4%; why are pharma stocks falling today?

Pharma shares crash: In the past four weeks, the Nifty Pharma index has slipped 5 per cent, as against 0.19 per cent decline in the Nifty 50.

Jefferies upbeat on India CRDMO; initiates Buy on Cohance; upgrades Divi's

Jefferies is optimistic on India's CRDMO sector, given its evolution from quasi-chemical firms into strategic partners for innovators; check more details

Nifty Pharma down 1.5%: Granules, Biocon lead with over 2% fall; Here's why

Pharma stocks fell after Trump said tariffs will be imposed within a week, rising up to 250 per cent in 12-18 months

Laurus rallies 6%, hits new high on strong Q1; brokerages see more upside

Laurus stock price outlook: Given the higher-margin profile of CDMO and operating leverage as new manufacturing assets ramp, brokerage firms expect sustained margin expansion.

Glenmark, Laurus: 4 pharma stocks gain up to 79% in 5 months; time to exit?

The daily RSI, a key momentum indicator, shows that these 4 pharma stocks namely - Gland Pharma, Glenmark, Biocon and Laurus Labs are trading in the overbought territory; here's what to expect next.

Glenmark, Laurus Lab: Will Trump's 200% tariff threat derail pharma stocks?

Donald Trump threatens of a potential 200% tariff on pharma imports; can this derail the rally in pharma shares, which have gained up to 50% in 3 months. Here's what the technical charts suggest.

Laurus up for 9th straight day, soars 23% in 1 month. What's driving stock?

Scale-up of the CDMO segment in FY26, is expected to contribute meaningfully to revenue growth and margin expansion, aided by better capacity utilisation and operational execution, CareEdge Ratings.

Laurus Labs nears record high after 4 years, zooms 84% from 52-week low

Laurus Labs management sees a clear pathway for further margin expansion as the company continue delivering on mid-late phase projects, ramping up new assets, and better asset utilisation.